These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 27882532)

  • 1. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
    Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
    Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
    J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
    Garnock-Jones KP
    Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
    Zmira O; Halpern AI; Abraham L; Achiron A
    Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
    Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab treatment of multiple sclerosis.
    Coles AJ
    Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
    Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus.
    Sprangers B; Decoo D; Dive D; Lysandropoulos A; Vanopdenbosch L; Bovy C
    Acta Neurol Belg; 2018 Jun; 118(2):143-151. PubMed ID: 29189966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
    Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
    Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y
    Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
    Ziemssen T; Engelmann U; Jahn S; Leptich A; Kern R; Hassoun L; Thomas K
    BMC Neurol; 2016 Jul; 16():109. PubMed ID: 27430352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
    Barclay K; Carruthers R; Traboulsee A; Bass AD; LaGanke C; Bertolotto A; Boster A; Celius EG; de Seze J; Cruz DD; Habek M; Lee JM; Limmroth V; Meuth SG; Oreja-Guevara C; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV
    Front Neurol; 2019; 10():253. PubMed ID: 30967831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.